Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NORTHWEST BIOTHERAPEUTICS INCNWBO · Entity 5982 | CHIEF TECHNICAL OFFICER | August 09, 2024 | August 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NORTHWEST BIOTHERAPEUTICS INC
Report date August 09, 2024 · Filed August 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| STOCK OPTIONSSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2030-07-02 | Direct | 4,549,157 |
Reported balance
After 2024-08-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-09 · Gift · Disposed 3,000,000 · Balance 4,549,157 F1: GIFT FROM DR. BOSCH TO FAMILY MEMBERS WHO DO NOT SHARE SAME RESIDENCE FOR ESTATE PLANNING PURPOSES |
Filing footnotes · ownership attribution and instrument terms
F1: GIFT FROM DR. BOSCH TO FAMILY MEMBERS WHO DO NOT SHARE SAME RESIDENCE FOR ESTATE PLANNING PURPOSES
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2024 Filed Aug 13, 2024 20:01 UTC | NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 | GiftSTOCK OPTIONS · Derivative | 3,000,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001104659-24-088927 · tm2421584-1_4seq1.xml · derivative · entry 1 BOSCH MARNIX L · CIK 0001253933 · CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,549,157 Underlying: COMMON STOCK PAR VALUE $0.001 · 3,000,000 shares Expires 2030-07-02 F1 · kind: GIFT FROM DR. BOSCH TO FAMILY MEMBERS WHO DO NOT SHARE SAME RESIDENCE FOR ESTATE PLANNING PURPOSES Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 23:31 UTC | NORTHWEST BIOTHERAPEUTICS INC NWBO] · Entity 5982 | GrantCommon Stock | 119,355 | $0.25 | $29,838.75 |
DisclosureSEC source: 0001104659-23-042303 · tm2311932-1_4seq1.xml · nonDerivative · entry 1 BOSCH MARNIX L · CIK 0001253933 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,355 F1 · kind: On April 3, 2023, Dr. Bosch was issued 119,355 shares of the Company's common stock pursuant to his exercise of certain options that were awarded in 2017. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 01:55 UTC | NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 | GrantOptions to purchase Common Stock, par value $0.001 · Derivative | 16,630,726 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001104659-20-080809 · tm2022243d9_4.xml · derivative · entry 1 BOSCH MARNIX L · CIK 0001253933 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,630,726 Underlying: Common Stock, par value $0.001 · 16,630,726 shares Expires 2030-12-01 F1 · kind: These options were awarded in part for service during the last 2 years. However, the documents to implement and issue (grant) them have not been executed until now. The $0.25 exercise price was determined with reference to the pricing for unrelated investors at the time of approval, which was the trailing 10-day average closing market price of the Company's stock, which was about $0.22. These options are subject to certain vesting requirements. They are also suspended and will not become exercisable until December 1, 2020. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 01:55 UTC | NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 | GrantOptions to purchase Common Stock, par value $0.001 · Derivative | 3,249,572 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001104659-20-080810 · tm2022243d10_4.xml · derivative · entry 2 BOSCH MARNIX L · CIK 0001253933 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,249,572 Underlying: Common Stock, par value $0.001 · 3,249,572 shares Expires 2030-07-02 F2 · kind: These options were approved in January 2020. The exercise price was determined based upon the pricing in year-end financings with unrelated investors. However, these options have not been executed and implemented (granted) until now. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 01:55 UTC | NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 | GrantOptions to purchase Common Stock, par value $0.001 · Derivative | 7,549,157 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001104659-20-080810 · tm2022243d10_4.xml · derivative · entry 1 BOSCH MARNIX L · CIK 0001253933 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,549,157 Underlying: Common Stock, par value $0.001 · 7,549,157 shares Expires 2030-07-02 F1 · kind: These options were already approved and publicly reported in 2018. The exercise price was determined with reference to the pricing for unrelated investors at that time. However, the documents to implement and issue (grant) them have not been executed until now. Read SEC document |
| June 13, 2017 Filed Jun 29, 2017 20:25 UTC | NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,940,182 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001144204-17-034899 · v469635_4.xml · derivative · entry 1 BOSCH MARNIX L · CIK 0001253933 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,940,182 Underlying: Common Stock · 7,940,182 shares Expires 2022-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option's vesting schedule is as follows: 50% vested upon the date of grant with the remaining 50% vesting over a 24-month period in equal monthly installments Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.